Eli Lilly has strengthened its lead in the obesity treatment sector, thanks to its successful drugs Mounjaro and Zepbound, which have significantly driven sales. However, competition intensifies as Novo Nordisk recently launched a GLP-1 pill, potentially threatening Eli Lilly's market share. As Eli Lilly prepares for the launch of its own oral GLP-1 drug, Orforglipron, analysts project a substantial revenue increase, yet the fierce rivalry in this booming market raises critical concerns for its growth trajectory.
“Novo Nordisk just beat Eli Lilly to market with a GLP-1 pill, giving this competitor an opportunity to regain market share.”
“Eli Lilly is racing to catch up with European rival Novo Nordisk, whose FDA-approved Wegovy pill hit the U.S. market in January and has seen strong early sales.”
“However, the Denmark-based drugmaker has lost ground to its biggest competitor, Eli Lilly (NYSE: LLY), in the GLP-1 market.”
“Eli Lilly (LLY) -2.77%: Here are some of the important healthcare stories from this week.”
“Novo's stock falls as obesity drug falls short against Lilly's in trial. Eli Lilly (LLY) stock rose 4% following the news.”
“Eli Lilly's CAGR over the past 10 years has been an outrageous 29.9%, but that came after Lilly developed a compound that, in only its third full year on the market, topped the list of the world's best-selling drugs (and could become the top-selling medicine of all time).”
“Novo's stock falls as obesity drug falls short against Lilly's in trial. Novo Nordisk (NVO) stock sank 13% before the bell on Monday after its next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial.”
“Eli Lilly (LLY) stock rose 4% following the news.”
“Investors have been particularly optimistic about stocks in high-growth areas, from artificial intelligence and quantum computing to companies leading in the weight loss drug market. In this context, stocks including AI leader Nvidia, quantum innovator IonQ, and weight loss drug giant Eli Lilly each have skyrocketed.”
“This means that, if history is right, we could be at the start of a period of declines -- and recent concerns that I mentioned above, if they persist, could drive this movement.”
“Earnings are expected to jump 39.6% in 2026. Eli Lilly is trading with a forward P/E of 30. It’s not a value stock, but it’s not as expensive as Walmart.”
“Eli Lilly is a large pharmaceutical manufacturer which is making, among other things, weight loss drugs. It is set to launch a new weight loss pill this year.”
